As shown in Figure 4, the odds of vortioxetine treated patients achieving a ≥50% MADRS score reduction from baseline was about 3 times higher than placebo treated patients (Overall OR = 2.87 ...

Now, experts say they may have discovered an unlikely yet accessible treatment for the brain cancer glioblastoma — a ...

Takeda Pharmaceuticals and Lundbeck have jointly announced the submission of a New Drug Application (NDA) to the US FDA for the investigational agent vortioxetine. Vortioxetine (Lu AA21004 ...

Vortioxetine is an antidepressant used for the treatment of major depressive disorder (MDD) in adults and also investigated as a treatment for generalized anxiety disorder (GAD).

Background Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD). It is a selective serotonin (5-HT ...